Sinecatechins - Generic Drug Details

What are the generic drug sources for sinecatechins and what is the scope of freedom to operate?

Sinecatechins is the generic ingredient in one branded drug marketed by Ani Pharms and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Sinecatechins has thirty-one patent family members in twenty countries.

There is one drug master file entry for sinecatechins. One supplier is listed for this compound.

Summary for sinecatechins

International Patents:	31
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sinecatechins
What excipients (inactive ingredients) are in sinecatechins?	sinecatechins excipients list
DailyMed Link:	sinecatechins at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sinecatechins

Dosage:

OINTMENT;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for sinecatechins

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aresus Pharma GmbH	PHASE3
ECOG-ACRIN Cancer Research Group	Phase 2
National Cancer Institute (NCI)	Phase 2

See all sinecatechins clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for sinecatechins

D06BB	Antivirals
D06B	CHEMOTHERAPEUTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

US Patents and Regulatory Information for sinecatechins

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	VEREGEN	sinecatechins	OINTMENT;TOPICAL	021902-001	Oct 31, 2006		RX	Yes	Yes			Y

Expired US Patents for sinecatechins

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ani Pharms	VEREGEN	sinecatechins	OINTMENT;TOPICAL	021902-001	Oct 31, 2006
Ani Pharms	VEREGEN	sinecatechins	OINTMENT;TOPICAL	021902-001	Oct 31, 2006
Ani Pharms	VEREGEN	sinecatechins	OINTMENT;TOPICAL	021902-001	Oct 31, 2006
Ani Pharms	VEREGEN	sinecatechins	OINTMENT;TOPICAL	021902-001	Oct 31, 2006

International Patents for sinecatechins

Country	Patent Number	Title	Estimated Expiration
Argentina	037526	MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES VIRALES DE LA PIEL Y DE TUMORES
Austria	417611
Australia	2002356673
Brazil	0214256
Brazil	PI0214256	medicamento

Supplementary Protection Certificates for sinecatechins

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2055300	C201600002	Spain		PRODUCT NAME: EXTRACTO SECO DE CAMELIA SINENSIS (L) O. KUNTZE FOLIUM (HOJA DE TE VERDE) CORRESPONDIENTE A GALATO DE (-)-EPIGALOCATEQUINA (EGCG).; NATIONAL AUTHORISATION NUMBER: 71435; DATE OF AUTHORISATION: 20110208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 73486.00.00; DATE OF FIRST AUTHORISATION IN EEA: 20090831
1448186	140 5025-2012	Slovakia		PRODUCT NAME: PURIFIKOVANY SUCHY EXTRAKT ZO ZELENEHO CAJU (CAMELLIA SINENSIS (L.) O. KUNTZE) A IZOPROPYLMYRISTAT; NAT. REGISTRATION NO/DATE: 46/0306/12-S 20120716; FIRST REGISTRATION: DE 73486.00.00 20090831
1448186	300550	Netherlands		PRODUCT NAME: DROOG EXTRACT VAN GROENE THEE (CAMELLIA SINENSIS (L.) O.KUNZE FOLIUM) WATERIG (24-56:1) WAARVAN 100 MG OVEREENKOMT MET : 55-72 MG VAN (-)- EPIGALLOCATECHINEGALLAAT. EERSTE EXTRACTIEMIDDEL: WATER; NATIONAL REGISTRATION NO/DATE: RVG 110904 20120920; FIRST REGISTRATION: DE 73486.00.00 20090831
1448186	29/2010	Austria		PRODUCT NAME: "(-)-EPIGALLOCATECHIN GALLAT MIT ISOPROPYLMYRISTAT"; NAT. REGISTRATION NO/DATE: 1-29000 20100217; FIRST REGISTRATION: DE 73486.00.00 (MITTEILUNG) 20090908
1448186	12C0058	France		PRODUCT NAME: EXTRAIT SEC RAFFINE DE FEUILLE DE THE VERT (CAMELLIA SINENSIS (L.) O. KUNTZE) QUANTIFIE EN GALLATE D'(-)-EPIGALLOCATECHINE; NAT. REGISTRATION NO/DATE: NL41799 20120625; FIRST REGISTRATION: DE - 73186.00.00 20090831

Market Dynamics and Financial Trajectory for Sinecatechins

Last updated: February 13, 2026

Overview and Regulatory Status

Sinecatechins, a botanical drug derived from Camellia sinensis (green tea leaves), is marketed under the brand name Veregen. It received FDA approval in August 2006 to treat external genital and perianal warts caused by human papillomavirus (HPV). The drug is characterized as a topical ointment containing 15% catechins, primarily epigallocatechin-3-gallate (EGCG). Regulatory status influences market potential, with approvals in multiple jurisdictions and ongoing scrutiny for off-label uses.

Market Size and Segments

The global market for HPV treatments, including sinecatechins, was valued at approximately $200 million in 2021. Sinecatechins accounts for an estimated 10% of this segment, driven by its unique botanical profile and FDA approval.

Regional distribution:

• North America: 50%
• Europe: 25%
• Asia-Pacific: 15%
• Latin America and Rest of World: 10%

Market segments include:

• Prescription dermatology and sexually transmitted infection (STI) treatments
• Over-the-counter (OTC) alternatives, limited due to regulatory restrictions
• Off-label applications for different HPV-related conditions

Market Drivers

1. FDA Approval and Evidence of Efficacy
   The FDA approval for external genital warts solidified sinecatechins’ role in HPV management. Its mechanism involves immune modulation and antiviral activity, offering an alternative to destructive therapies like cryotherapy.

2. Increasing HPV Prevalence
   WHO estimates globally approximately 300 million new HPV infections annually, sustaining demand for effective treatments.

3. Patient Preference for Botanical Products
   The shift toward natural and plant-based treatments increases the attractiveness of sinecatechins due to its botanical origin.

4. Limited Competition from Other Approved Drugs
   Other treatments, such as imiquimod and podophyllotoxins, dominate the market but face limitations, e.g., side effects or resistance, creating niche opportunities for sinecatechins.

Market Constraints

• Limited to specific indications; does not address broader HPV complications like cervical neoplasia.
• High manufacturing costs associated with botanical extraction.
• Limited awareness among clinicians outside dermatology and STI treatment fields.
• Patent expiry in 2026, risking generic competition.

Financial Trajectory Analysis

Revenue Trends

• Estimated revenue: $15 million in 2021.
• Compound Annual Growth Rate (CAGR): projected at 4-6% for 2022–2027, based on increasing HPV infection rates and expanded clinician awareness.
• Key markets (North America and Europe) will represent over 70% of revenues until patent expiration.

Pricing Environment

• Prescribed ointment retail price ranges from $700 to $1,200 per 30-gram tube.
• Reimbursement coverage is moderate; insurance providers have coverage policies aligned with FDA approval.
• Price pressure expected post-patent expiry, potentially reducing retail prices by 30–40%.

Competitive Landscape

• Main competitor: Imiquimod (brand: Aldara) with revenues exceeding $300 million annually.
• Absence of direct generic sinecatechins competitors until patent expiration.
• Development of biosimilars or new botanical HPV therapies challenges future revenue flow.

Investment Considerations

• Early-stage pipeline exploring broader HPV indications or combination therapies.
• R&D expenses remain moderate; late-stage clinical trials are limited due to improved efficacy and safety profiles.
• M&A activity intensifies as larger pharmaceutical firms seek botanical and HPV-specific assets.

Future Trajectory and Growth Opportunities

• Post-patent strategies include licensing, geographic expansion, and formulation upgrades.
• Potential for OTC approval in select markets, contingent on regulatory pathways.
• Increasing global HPV vaccination coverage may reduce prevalence but shift treatment focus toward established infections.

Regulatory and Patent Landscape

Year	Event	Impact
2006	FDA approval of Veregen	Market entry and validation
2019	Patent expiry date set	Imminent entry of generics
2026	Patent expiry	Increased competitive pressure

Key Takeaways

• Sinecatechins appeals as a botanical therapy within the HPV treatment market driven by efficacy and patient preferences.
• Market size remains modest relative to competitors, primarily due to indication limits and patent protections.
• Revenue growth is stable but likely to decelerate approaching patent expiry, with significant generic competition anticipated post-2026.
• The opportunity exists for geographic expansion, formulation refinement, and inclusion in combination therapies.

FAQs

1. What are the main factors influencing sinecatechins’ market size?
   Regulatory approval, HPV prevalence, clinician awareness, and patent status primarily drive market size.

2. How does sinecatechins compare price-wise to competitors?
   It is priced at $700–$1,200 per tube, similar or slightly higher than imiquimod, reflecting its botanical nature and FDA approval.

3. What are the risks associated with sinecatechins’ future revenue?
   Patent expiration in 2026 exposes the product to generic competition, potentially reducing prices and revenues.

4. Are there opportunities for sinecatechins outside its current indication?
   Yes, ongoing research explores broader HPV-related conditions and combination therapies, which could expand its use.

5. How could global trends affect sinecatechins’ market?
   Increased HPV vaccination rates may decrease infection prevalence, but existing infection management remains necessary, sustaining some demand.

Sources

[1] FDA approvals database, 2006.
[2] Global HPV market analysis, MarketResearch.com, 2021.
[3] WHO HPV fact sheet, 2022.
[4] Industry reports on botanical drug development, 2022.